Decreased hepatic peroxisome proliferator-activated receptor-γ contributes to increased sensitivity to endotoxin in obstructive jaundice

Figure 1 Modified measurement of peroxisome proliferator-activated receptor-γ activation and expression upon bile duct ligation and consequent cholestasis. A: Electrophoretic mobility shift assay (top panel) of peroxisome proliferator-activated receptor (PPAR)-γ. DNA binding in nuclear extracts from liver, and relative densitometric analysis (lower panel). Data are expressed as mean ± SE (n = 3). ^aP < 0.05 for bile duct ligation (BDL) group vs sham group; B: PPAR-γ mRNA expression in the liver. PPAR-γ expression in the liver of BDL rats decreased significantly compared with the sham-group determined by quantitative real-time reverse transcription-polymerase chain reaction. Data are expressed as mean ± SE (n = 6). ^bP < 0.01 for BDL group vs sham group; C: Western blotting analysis (top panel) of PPAR-γ in nuclear extracts from liver, and relative densitometric analysis (lower panel, n = 3). Data are expressed as mean ± SE (n = 3). ^bP < 0.01 for BDL group vs sham group.

Figure 2 Survival rates of rats after administration of lipopolysaccharide (3 mg/kg, i. p.). The survival curve was estimated by the Kaplan-Meier method and the log-rank method was used to compare differences in survival rates between groups (n = 20). ^aP < 0.01 for bile duct ligation group vs sham group. BDL: Bile duct ligation; LPS: Lipopolysaccharide.

Figure 3 Effects of pretreatment with rosiglitazone (3 mg/kg, i. p.) on survival rates in rats after administration of lipopolysaccharide (6 mg/kg for sham-group and 3 mg/kg for bile duct ligation group, i.p.). The survival curve was estimated by the Kaplan-Meier method and the log-rank method was applied to compare differences in survival rates between groups (n = 20). Rosiglitazone pretreatment significantly improve the survival in sham + lipopolysaccharide (LPS) (6 mg/kg) group but not in bile duct ligation + LPS (3 mg/kg) group, ^aP < 0.05 vs sham + LPS group. BDL : Bile duct ligation; ROSI: Rosiglitazone.